Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas

Amber Tong

Putting immuno-oncology front and center in its R&D strategy, Astellas has brought in a low-profile team to help hunt for its next wave of therapies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas

Amber Tong

Sign up to read this article for free.

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

Amber Tong

Sign up to read this article for free.

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks